Research Activity
Denali and AbbVie’s ALS Candidates Fail Phase 2/3 Trials, Highlighting Challenges in ALS Research
ALS, Denali Therapeutics, AbbVie, Calico Life Sciences, HEALEY ALS Platform Trial, DNL343, fosigotifator, amyotrophic lateral sclerosis, clinical trials, drug development
Truveta Genome Project: A Historic 10M Genome Sequencing Initiative Backed by Regeneron, Illumina, and Leading Health Systems
Truveta Genome Project, 10M genome sequencing, Regeneron, Illumina, genetic sequencing, genotypic and phenotypic data, healthcare analytics, drug discovery, personalized medicine.
Eli Lilly and Mediar Therapeutics Collaborate on Novel IPF Treatment with $780M+ Deal
Eli Lilly, Mediar Therapeutics, Idiopathic Pulmonary Fibrosis (IPF), MTX-463, WISP1 antibody, fibrosis treatment, licensing agreement, clinical trials.
Marea Therapeutics Announces Breakthrough Phase II Results for MAR001, a Novel Monoclonal Antibody Targeting Remnant Cholesterol
Marea Therapeutics, MAR001, Remnant Cholesterol, Monoclonal Antibody, Cardiovascular Disease, ANGPTL4, Phase II Clinical Trial
Tune Therapeutics Secures $175M to Advance Epigenetic Editing into Clinical Trials
Epigenetic editing, gene therapy, Tune Therapeutics, clinical trials, biotech funding
Accelerating Alzheimer’s Research: The Alzheimer’s Drug Discovery Foundation
Alzheimer’s disease, drug discovery, research funding, venture philanthropy, cognitive aging, dementia treatments
Light Horse Therapeutics Secures $1 Billion+ Novartis Collaboration on Launch Day
Light Horse Therapeutics, Novartis, biotech, strategic collaboration, small molecule therapeutics, precision genome editing, drug discovery
Scribe Therapeutics Prepares for Clinical Trials by Streamlining Workforce Amid Advances in Cardiometabolic Genetic Medicines
Scribe Therapeutics, cardiometabolic disease, CRISPR, gene editing, epigenetic modification, clinical trials, workforce reduction
Revival of Dormant Antipsychotic Class: LB Pharma’s Phase II Success with LB-102
LB Pharma, LB-102, Antipsychotic drugs, Schizophrenia treatment, Phase II clinical trials, Benzamide antipsychotics
Novo Nordisk and Valo Health Expand AI-Driven Collaboration to Develop Novel Treatments for Obesity, Type 2 Diabetes, and Cardiovascular Disease
Novo Nordisk, Valo Health, AI, Obesity, Type 2 Diabetes, Cardiovascular Disease, Drug Development, Computational Biotech